ECSP088166A - Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina - Google Patents
Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecinaInfo
- Publication number
- ECSP088166A ECSP088166A EC2008008166A ECSP088166A ECSP088166A EC SP088166 A ECSP088166 A EC SP088166A EC 2008008166 A EC2008008166 A EC 2008008166A EC SP088166 A ECSP088166 A EC SP088166A EC SP088166 A ECSP088166 A EC SP088166A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitor
- compositions
- topoisomerasa
- butoxiiminometilcamptotecina
- ter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas en micropartículas, en donde el agente activo es un inhibidor de topoisomerasa I, en particular 7-t-butoxiiminometilcamptotecina, que es útil para el tratamiento y la prevención de enfermedades proliferativas, incluyendo cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70713905P | 2005-08-10 | 2005-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088166A true ECSP088166A (es) | 2008-03-26 |
Family
ID=37056484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008166A ECSP088166A (es) | 2005-08-10 | 2008-02-08 | Composiciones en micro partículas del inhibidor de topoisomerasa i 7-ter-butoxiiminometilcamptotecina |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1915132A1 (es) |
JP (1) | JP2009504616A (es) |
KR (1) | KR20080034989A (es) |
CN (1) | CN101287448A (es) |
AR (1) | AR055602A1 (es) |
AU (1) | AU2006277879A1 (es) |
BR (1) | BRPI0614757A2 (es) |
CA (1) | CA2618084A1 (es) |
EC (1) | ECSP088166A (es) |
GT (1) | GT200600364A (es) |
IL (1) | IL189076A0 (es) |
MA (1) | MA29735B1 (es) |
MX (1) | MX2008001965A (es) |
NO (1) | NO20081213L (es) |
PE (1) | PE20070232A1 (es) |
RU (1) | RU2008108885A (es) |
TN (1) | TNSN08062A1 (es) |
TW (1) | TW200800195A (es) |
WO (1) | WO2007017514A1 (es) |
ZA (1) | ZA200800726B (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
IT1306129B1 (it) * | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
GT200500310A (es) * | 2004-11-19 | 2006-06-19 | Compuestos organicos |
-
2006
- 2006-08-08 JP JP2008525580A patent/JP2009504616A/ja active Pending
- 2006-08-08 CA CA002618084A patent/CA2618084A1/en not_active Abandoned
- 2006-08-08 KR KR1020087005632A patent/KR20080034989A/ko not_active Application Discontinuation
- 2006-08-08 WO PCT/EP2006/065160 patent/WO2007017514A1/en active Application Filing
- 2006-08-08 AU AU2006277879A patent/AU2006277879A1/en not_active Abandoned
- 2006-08-08 BR BRPI0614757-7A patent/BRPI0614757A2/pt not_active IP Right Cessation
- 2006-08-08 AR ARP060103450A patent/AR055602A1/es not_active Application Discontinuation
- 2006-08-08 RU RU2008108885/15A patent/RU2008108885A/ru not_active Application Discontinuation
- 2006-08-08 PE PE2006000965A patent/PE20070232A1/es not_active Application Discontinuation
- 2006-08-08 TW TW095129044A patent/TW200800195A/zh unknown
- 2006-08-08 MX MX2008001965A patent/MX2008001965A/es not_active Application Discontinuation
- 2006-08-08 CN CNA200680037599XA patent/CN101287448A/zh active Pending
- 2006-08-08 EP EP06792739A patent/EP1915132A1/en not_active Withdrawn
- 2006-08-08 GT GT200600364A patent/GT200600364A/es unknown
-
2008
- 2008-01-24 ZA ZA200800726A patent/ZA200800726B/xx unknown
- 2008-01-28 IL IL189076A patent/IL189076A0/en unknown
- 2008-02-08 MA MA30631A patent/MA29735B1/fr unknown
- 2008-02-08 TN TNP2008000062A patent/TNSN08062A1/en unknown
- 2008-02-08 EC EC2008008166A patent/ECSP088166A/es unknown
- 2008-03-07 NO NO20081213A patent/NO20081213L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TNSN08062A1 (en) | 2009-07-14 |
EP1915132A1 (en) | 2008-04-30 |
JP2009504616A (ja) | 2009-02-05 |
AR055602A1 (es) | 2007-08-29 |
CN101287448A (zh) | 2008-10-15 |
MX2008001965A (es) | 2008-03-26 |
BRPI0614757A2 (pt) | 2011-04-12 |
WO2007017514A1 (en) | 2007-02-15 |
ZA200800726B (en) | 2009-08-26 |
MA29735B1 (fr) | 2008-09-01 |
AU2006277879A1 (en) | 2007-02-15 |
KR20080034989A (ko) | 2008-04-22 |
RU2008108885A (ru) | 2009-09-20 |
CA2618084A1 (en) | 2007-02-15 |
NO20081213L (no) | 2008-05-13 |
IL189076A0 (en) | 2008-08-07 |
PE20070232A1 (es) | 2007-04-09 |
TW200800195A (en) | 2008-01-01 |
GT200600364A (es) | 2007-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
PH12017501306A1 (en) | Inhibitors of histone demethylases | |
DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
IN2012DN02018A (es) | ||
CR20140108A (es) | Compuesto de ciclopropanoamina | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
GT200600194A (es) | Composiciones farmaceuticas conteniendo imatinib y un componente de liberacion prolongada | |
UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
MY198422A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
UY30905A1 (es) | Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2010001474A1 (es) | Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares. | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
DOP2010000302A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
CU24349B1 (es) | Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer | |
BRPI0518448A2 (pt) | composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina | |
ECSP088745A (es) | Derivados sustituidos de cromanol y su uso | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BRPI1015539A2 (pt) | composições e métodos para tratamento de queimaduras | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
CR10524A (es) | Compuesto triciclico y uso farmaceutico del mismo |